TEMOZOLOMIDE & BCNU FOR ANAPLASTIC GLIOMAS

替莫唑胺

• 批准号: 6303480
• 负责人: HARRY S GREENBERG
• 金额: $ 0.02万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-01 至 2001-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6303480
• 关键词: astrocytoma; carmustine; clinical research; combination chemotherapy; glioma; human subject; human therapy evaluation; neoplasm /cancer chemotherapy; temozolomide

The purpose of this study is to determine how patients with brain tumors respond to the combination of the chemotherapy drugs temozolomide and BCNU, and how long their response lasts when treated with this combination. If this treatment works, it may cause your tumor to shrink and prolong your life and/or improve the quality of your life. We also want to find out what kind of side effects these drugs cause in combination and how often they occur. Patients with glioblastoma multiforme, a type of malignant glioma, must have failed treatment with surgery and radiation and may or may not have chemotherapy. Patients with anaplastic glioma must not have had postoperative treatment with radiation or chemotherapy. Patients will receive treatments every six weeks and will be followed with MRI scans for response determination.

本研究的目的是确定脑肿瘤患者对化疗药物替莫唑胺和 BCNU 组合的反应如何，以及用这种组合治疗时他们的反应持续多长时间。 如果这种治疗有效，可能会导致您的肿瘤缩小并延长您的生命和/或改善您的生活质量。 我们还想了解这些药物联合使用会产生什么样的副作用以及它们发生的频率。 多形性胶质母细胞瘤（一种恶性胶质瘤）患者必须经过手术和放射治疗失败，并且可能接受或不接受化疗。 间变性胶质瘤患者不得接受术后放疗或化疗治疗。 患者将每六周接受一次治疗，并进行 MRI 扫描以确定疗效。